Clinical Trials Browser

Phase 1 × INDUSTRY × mirdametinib × Clear all

NCT03905148 2026-01-07

Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumor, Adult

NCT01347866 2018-10-29

Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

Phase 1 Terminated

105 enrolled 64 charts

Advanced Cancer